BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 29738953)

  • 41. Beyond the Selective Inhibition of Histone Deacetylase 6.
    Rodrigues DA; Thota S; Fraga CA
    Mini Rev Med Chem; 2016; 16(14):1175-84. PubMed ID: 27121714
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Re-exploration of tetrahydro-β-carboline scaffold: Discovery of selective histone deacetylase 6 inhibitors with neurite outgrowth-promoting and neuroprotective activities.
    Wen W; Hu J; Wang C; Yang R; Zhang Y; Huang B; Qiao T; Wang J; Chen X
    Bioorg Med Chem Lett; 2024 Apr; 102():129670. PubMed ID: 38387692
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors.
    De Vreese R; D'hooghe M
    Eur J Med Chem; 2017 Jul; 135():174-195. PubMed ID: 28453994
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Isoform-selective HDAC1/6/8 inhibitors with an imidazo-ketopiperazine cap containing stereochemical diversity.
    Lecointre B; Narozny R; Borrello MT; Senger J; Chakrabarti A; Jung M; Marek M; Romier C; Melesina J; Sippl W; Bischoff L; Ganesan A
    Philos Trans R Soc Lond B Biol Sci; 2018 Jun; 373(1748):. PubMed ID: 29685969
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
    Li S; Zhao C; Zhang G; Xu Q; Liu Q; Zhao W; James Chou C; Zhang Y
    Bioorg Chem; 2021 Nov; 116():105278. PubMed ID: 34474303
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
    Zhang XH; Qin-Ma ; Wu HP; Khamis MY; Li YH; Ma LY; Liu HM
    J Med Chem; 2021 Feb; 64(3):1362-1391. PubMed ID: 33523672
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects.
    Vishwakarma S; Iyer LR; Muley M; Singh PK; Shastry A; Saxena A; Kulathingal J; Vijaykanth G; Raghul J; Rajesh N; Rathinasamy S; Kachhadia V; Kilambi N; Rajgopal S; Balasubramanian G; Narayanan S
    Int Immunopharmacol; 2013 May; 16(1):72-8. PubMed ID: 23541634
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
    Soumyanarayanan U; Ramanujulu PM; Mustafa N; Haider S; Fang Nee AH; Tong JX; Tan KSW; Chng WJ; Dymock BW
    Eur J Med Chem; 2019 Dec; 184():111755. PubMed ID: 31627059
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.
    Wu H; Yang K; Zhang Z; Leisten ED; Li Z; Xie H; Liu J; Smith KA; Novakova Z; Barinka C; Tang W
    J Med Chem; 2019 Aug; 62(15):7042-7057. PubMed ID: 31271281
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma.
    Nepali K; Hsu TI; Hsieh CM; Lo WL; Lai MJ; Hsu KC; Lin TE; Chuang JY; Liou JP
    Eur J Med Chem; 2021 May; 217():113338. PubMed ID: 33744690
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
    Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
    Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
    Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
    ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of Hybrid-polar Histone Deacetylase Inhibitor m-Carboxycinnamic Acid bis-Hydroxyamide on Human Pancreatic Adenocarcinoma Cells.
    Kumar D; Sarma P; Bhadra MP; Tangutur AD
    Anticancer Agents Med Chem; 2019; 19(6):750-759. PubMed ID: 30621566
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine γ-lyase protein degradation.
    Chi Z; Byeon HE; Seo E; Nguyen QT; Lee W; Jeong Y; Choi J; Pandey D; Berkowitz DE; Kim JH; Lee SY
    Pharmacol Res; 2019 Aug; 146():104281. PubMed ID: 31125601
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors.
    Tavares MT; Kozikowski AP; Shen S
    Eur J Med Chem; 2021 Jan; 209():112887. PubMed ID: 33035922
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019).
    He X; Li Z; Zhuo XT; Hui Z; Xie T; Ye XY
    Recent Pat Anticancer Drug Discov; 2020; 15(1):32-48. PubMed ID: 32065106
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metal-Free Direct Amidation of Naphthoquinones Using Hydroxamic Acids as an Amide Source: Application in the Synthesis of an HDAC6 Inhibitor.
    Zhang C; Chou CJ
    Org Lett; 2016 Nov; 18(21):5512-5515. PubMed ID: 27759399
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models.
    Depetter Y; Geurs S; De Vreese R; Goethals S; Vandoorn E; Laevens A; Steenbrugge J; Meyer E; de Tullio P; Bracke M; D'hooghe M; De Wever O
    Int J Cancer; 2019 Aug; 145(3):735-747. PubMed ID: 30694564
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HDAC6 Modulates Signaling Pathways Relevant to Synaptic Biology and Neuronal Differentiation in Human Stem-Cell-Derived Neurons.
    Iaconelli J; Xuan L; Karmacharya R
    Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30935091
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
    Xie R; Li Y; Tang P; Yuan Q
    Eur J Med Chem; 2018 Jan; 143():320-333. PubMed ID: 29202397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.